ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1570

Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning
Abstract Number: 1571

Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
Abstract Number: 1572

CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Abstract Number: 1574

Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Abstract Number: 1575

Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Abstract Number: 1576

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
Abstract Number: 1577

Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
Abstract Number: 1578

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Abstract Number: 1579

The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Abstract Number: 1580

Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Abstract Number: 1581

Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study
Abstract Number: 1582

Allopurinol Use and Risk of Acute Coronary Syndrome in Patients with Incident Gout: A Population-based Study in Sweden
Abstract Number: 1583

Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Abstract Number: 1584

Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition Arthritis: A Multicenter Randomized Controlled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].